These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15241439)

  • 61. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood.
    Hayashi H; Nishiuchi T; Tamura H; Takeda K
    Anesthesiology; 1993 Dec; 79(6):1419-21. PubMed ID: 8267214
    [No Abstract]   [Full Text] [Related]  

  • 62. Donor lymphocyte infusions as primary therapy for neoplasms.
    Montefusco V
    Blood; 2003 Jan; 101(1):373; author reply 373-4. PubMed ID: 12485941
    [No Abstract]   [Full Text] [Related]  

  • 63. Defining a TCF1-expressing progenitor allogeneic CD8
    Lee S; Lee K; Bae H; Lee K; Lee J; Ma J; Lee YJ; Lee BR; Park WY; Im SJ
    Nat Commun; 2023 Sep; 14(1):5869. PubMed ID: 37737221
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.
    Chakraverty R; Sykes M
    Blood; 2007 Jul; 110(1):9-17. PubMed ID: 17327406
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
    Hoevenaren IA; van Vulpen LF; Levenga H; Minnema MC; Raymakers R
    Bone Marrow Transplant; 2011 Feb; 46(2):319-21. PubMed ID: 20305701
    [No Abstract]   [Full Text] [Related]  

  • 66. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
    Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
    Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
    Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
    Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma.
    Ayuk F; Shimoni A; Nagler A; Schwerdtfeger R; Kiehl M; Sayer HG; Zabelina T; Zander AR; Kröger N
    Leukemia; 2004 Mar; 18(3):659-62. PubMed ID: 14671630
    [No Abstract]   [Full Text] [Related]  

  • 69. Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion?
    Peggs K; Mackinnon S
    Leukemia; 2004 Sep; 18(9):1541-2; author reply 1542-3. PubMed ID: 15241439
    [No Abstract]   [Full Text] [Related]  

  • 70. Multiple myeloma: role of allogeneic transplantation.
    Pandit S; Vesole DH
    Oncology (Williston Park); 2002 Sep; 16(9):1268-74; discussion 1274-6. PubMed ID: 12380950
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
    Zeiser R; Finke J
    Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Roles of transforming growth factor-β in graft-versus-host and graft-versus-tumor effects.
    Carli C; Giroux M; Delisle JS
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1329-40. PubMed ID: 22326303
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.
    Zeiser R; Bertz H; Spyridonidis A; Houet L; Finke J
    Bone Marrow Transplant; 2004 Dec; 34(11):923-8. PubMed ID: 15361911
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.